<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986518</url>
  </required_header>
  <id_info>
    <org_study_id>P080601</org_study_id>
    <nct_id>NCT00986518</nct_id>
  </id_info>
  <brief_title>T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study</brief_title>
  <acronym>STARTREK</acronym>
  <official_title>Controlled and Selective Depletion of Regulatory T-cell for Cancer Treatment, Efficacy and Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      T regulatory lymphocytes were shown to be partly responsible for immune tolerance to cancer&#xD;
      cells. In that respect these cells oppose to the mounting of an efficacious immune response&#xD;
      needed to cure cancer. To treat advanced metastatic colorectal cancer, the investigators&#xD;
      propose an immunotherapy consisting in autologous lymphocytes infusion depleted from&#xD;
      T-regulatory cells, associated with a 5-day prior lymphoid-ablative chemotherapy associating&#xD;
      cyclophosphamide (day 1 &amp; 2) with fludarabine (day 1 to 5). To administer treatment and&#xD;
      monitor chemotherapy safety, patients will be hospitalized for 3 weeks until complete&#xD;
      recovery from chemotherapy. Patients will then be followed-up ambulatory for 9 months during&#xD;
      which time they will be assessed for tumor size with computed tomography (CT) - scan (primary&#xD;
      criteria).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of the proposed clinical trial is to eliminate cancer tumor using an&#xD;
      autologous cell therapy aiming at mounting an efficient immune anti-tumor response by&#xD;
      selectively depleting regulatory T-cell during a controlled amount of time. This strategy&#xD;
      will be tested in patients with hepatic metastases from colorectal who are not eligible for&#xD;
      surgery.&#xD;
&#xD;
      This is an open-label single cohort phase I-II therapeutic trial. Patients with hepatic&#xD;
      metastases from primary colorectal cancer, not eligible to surgery and relapsing from&#xD;
      conventional chemotherapy and/or targeted therapy, will be included.&#xD;
&#xD;
      Following patient inclusion:&#xD;
&#xD;
        1. A lymphapheresis will be performed at D-15 which will be subjected to cell sorting&#xD;
           /purification of regulatory T cells on the one hand and T lymphocytes depleted from&#xD;
           regulatory T cells (effectors T-cells) on the other, and subsequently frozen and stored&#xD;
           (The procedures for ex vivo regulatory T cell depletion has been validated in a previous&#xD;
           study - AFSSAPS- TC 192) ;&#xD;
&#xD;
        2. A lymphoid-ablative chemotherapy (cyclophosphamide + fludarabine) will be perform from&#xD;
           D1 to D5,&#xD;
&#xD;
        3. Autologous effector T-cells administration will be performed at D7. Efficacy will be&#xD;
           assessed through tumor size change. Change in tumor size will be assessed with CTscans&#xD;
           (RECIST criteria), MRIs (functional criteria following injection: DCEMRI and diffusion&#xD;
           MRI to assess change in cellularity and tumor necrosis and morphological criteria&#xD;
           RECIST), and sonography with contrast injection (to assess vascular microcirculation).&#xD;
           Assessments will be done prior to lymphoid-ablation and then monthly for 9 months.&#xD;
           Safety will be systematically assessed daily during in-patient period using the World&#xD;
           Health Organisation - Common Toxicity Criteria (WHO-CTC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor size of hepatic and/or lung metastases, as measured with tomodensitometry (RECIST 1.1 criteria)</measure>
    <time_frame>from Month 1 to Month 9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI : Assessment of tumor necrosis, cellularity and morphological criteria RECIST 1.1 (functional criteria following injection : DCEMRI and diffusion MRI)</measure>
    <time_frame>Month 1 to Month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sonography : assessment of vascular micro-circulation with contrast injection,</measure>
    <time_frame>Month 1 to Month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune cell reconstitution will be assessed through measuring rate of regulatory T-cell reconstitution,</measure>
    <time_frame>day 7 to 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Exam (WHO-CTC), Vital Signs, Adverse events</measure>
    <time_frame>day 1 to 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory test: hepatic function, immune function, haematology</measure>
    <time_frame>day 1 to 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>adaptive cell immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adaptive autologous cell immunotherapy</intervention_name>
    <description>each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.</description>
    <arm_group_label>adaptive cell immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Colon or rectal adenocarcinoma histologically proven;&#xD;
&#xD;
          -  Hepatic or lung metastasis (at least one with size &gt;1cm on CT-scan);&#xD;
&#xD;
          -  Not eligible for surgery;&#xD;
&#xD;
          -  Prior treatment with fluoropyrimidines, CPT11, oxaliplatine and EGFR antibodies&#xD;
             (Cetuximab ou Panitumumab) ± bevacizumab; When tumor has a mutated Kras, prior&#xD;
             treatment with EGFR antibodies is not mandatory;&#xD;
&#xD;
          -  No local recurrence (on CT-scan, sonogram and/or colonoscopy);&#xD;
&#xD;
          -  Karnofsky index &gt; 70 and PS 0 or 1;&#xD;
&#xD;
          -  ASA Score &lt; 3 ;&#xD;
&#xD;
          -  Absence of chronic hepatopathy ;&#xD;
&#xD;
          -  Lab test : WBC: neutrophil&gt; 2.0 109 / l, lymphocytes &gt; 1.5 109 / l; creatinine &lt; 1.5 x&#xD;
             ULN or clearance ≥ 60 ml/min; AST et ALT&lt; 5 x ULN, alkaline phosphatases &lt; 3 x ULN;&#xD;
             LDH &lt; 3 x ULN; negative Coombs test ;&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Peritoneal carcinosis on CT-scan, MRI or PET-scan;&#xD;
&#xD;
          -  Contra-indication to MRI;&#xD;
&#xD;
          -  Patient with known allergy to iodinated contrast agent, gadolinium or Sulfate&#xD;
             Hexafluoron ;&#xD;
&#xD;
          -  Presence of metastasis at sites other than lung and liver;&#xD;
&#xD;
          -  Documented history of auto-immune disease and/ or progressing disease;&#xD;
&#xD;
          -  Infection at whatever site;&#xD;
&#xD;
          -  Documented history of allo- or autograft;&#xD;
&#xD;
          -  Undernutrition, BMI &lt; 18;&#xD;
&#xD;
          -  History of other cancer &lt; 5 years (excluding cancer in situ of the cervix and&#xD;
             baso-cellular tumor of the skin) or progressing disease;&#xD;
&#xD;
          -  Women of child bearing age without contraception , or pregnant or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Klatzmann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié-Salpêtrière Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service hépato-gastro-enterologie, Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Colorectal Cancer</keyword>
  <keyword>Hepatic and/or lung metastasis</keyword>
  <keyword>Adaptive autologous cell immunotherapy</keyword>
  <keyword>T- regulatory lymphocyte depletion</keyword>
  <keyword>Neo-adjuvant reduced intensity chemotherapeutic conditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

